Drug profile · INN
neomycin sulfate
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
neomycin sulfate (NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: for rx compounding. Current US regulatory status: approved.
Drug details — neomycin sulfate
- US status
- approved
- Class
- —
- Route
- FOR RX COMPOUNDING
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
neomycin sulfate (NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: for rx compounding. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is neomycin sulfate?
neomycin sulfate (NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE) is a bacterial 70s ribosome inhibitor. Associated with Teva Pharma GmbH. Route of administration: for rx compounding. Current US regulatory status: approved.
What is the brand name for neomycin sulfate?
NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE is a marketed brand name for neomycin sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of neomycin sulfate?
neomycin sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.